Cardiac Troponin

for Earlier Diagnosis of Myocardial Infarctions

Time is Muscle – Earlier MI Diagnosis with Sensitive Troponin Assays
The detection of a rise and/or fall of cardiac troponin (cTn) plays a key role in the earlier diagnosis of myocardial infarction (MI). Cardiac troponins are markers of myocardial necrosis, and, because of their high cardiac-specificity, are the preferred biomarker for the diagnosis of MI.

Reliable Answers for Critical Needs
As a recognized worldwide leader in CVD testing, Siemens Healthineers is the only company offering multiple solutions for cardiac troponin I (cTnI) testing that meet the current guidelines for MI diagnosis*. Siemens’ cTnI assays provide excellent clinical sensitivity and precision for earlier detection of necrosis and MI than less-precise assays.

Preferred Biomarker of Cardiac Injury
Troponin is a complex of three contractile regulatory proteins, troponin C, T and I, that control the calcium mediated interactions between actin and myosin in cardiac and skeletal muscles.

  • Troponin I and T are specific to cardiac muscles, unlike troponin C which is associated with both cardiac and skeletal muscles.
  • Troponin C is not used in the diagnosis of myocardial damage.
  • Both Troponin I and Troponin T are released into circulation at the time of injury following the same release pattern in the system. However, cardiac Troponin I is slightly more differentiated from skeletal Troponin I than cardiac Troponin T is from skeletal Troponin T.

Cardiac troponins are released into circulation in response to myocardial necrosis. As such, cardiac troponins are the preferred biomarkers for the detection of cardiac injury, and have long assisted physicians in improving diagnostic strategies for the effective management of patients with chest pain.

  • Relatively non-specific markers of myocardial damage, such as creatine kinase (CK), creatine kinase-MB (CK-MB), and myoglobin (MYO), were used in diagnostic laboratories prior to the commercial release of the troponin assays.
  • Numerous clinical studies on troponin have indicated its superior cardiac specificity in comparison to CK, CK-MB, or MYO.
  • Troponin levels remain elevated in the blood longer than CK-MB or MYO, providing an extended diagnostic window for MI.
Contact Us

Clinical Guidelines

  • 99th percentile for cardiac troponin is appropriate cutoff for considering myocardial necrosis
  • For contemporary assays, serial cardiac troponin levels should be measured at presentation and 3 to 6 hours after symptom onset in all patients who present with chest pain symptoms. This identifies a rising and/or falling pattern
  • In evaluating serial changes, absolute changes appear to have a significantly higher diagnostic accuracy for AMI than relative changes

http://circ.ahajournals.org/content/130/25/e344

Cardiac Menu

Siemens is dedicated to providing quality cardiac assays that provide reliable answers to critical cardiac questions in every setting for every patient.

 

BNP

     √

     √

  

      √

 

 

CKMB Mass

     √

     √

       √

      √

      √

      √

CKMB Isoenzyme

 

 

       √

      √

 

 

D-Dimer

 

 

  

  

      √

      √

High-Sensitivity CRP

 

 

       √

      √

      √

      √

High-Sensitivity Troponin I

     √

     √†1

       √

      √

 

  

Myoglobin

     √

     √

       √

      √

      √

      √

NT-proBNP

     √

     √

       √

      √

 

      √

Tnl-Ultra™

     √

     √ǂ

  

  

 

  

Troponin I

 

  

       √ǂ

      √ǂ

      √

      √ǂ